Pulmonary Arterial Hypertension Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
Jul 5 LLY Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
Jul 5 LLY Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Jul 5 LLY Eli Lilly Remains an Equities Outlier
Jul 5 ASND Pendopharm and Ascendis to distribute hypoparathyroidism treatment
Jul 5 LLY Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
Jul 5 ASND Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
Jul 4 LLY Here's How Much $100 Invested In Eli Lilly and Co 15 Years Ago Would Be Worth Today
Jul 4 ASND Pendopharm signs distribution agreement with Ascendis Pharma for TransCon PTH in Canada
Jul 4 ASND Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada
Jul 4 LLY NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
Jul 4 LLY Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Jul 4 LLY FDA approves Eli Lilly’s Kisunla (donanemab) for early AD
Jul 4 LLY Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Jul 3 LLY Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst
Jul 3 LLY S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
Jul 3 LLY Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
Jul 3 LLY Weight-loss drugs linked to rare vision loss: Harvard study
Jul 3 LLY ADP jobs data, Constellation Brands, summer gas prices: Morning Brief
Jul 3 LLY Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
Jul 3 LLY FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags